Background An accurate biomarker is urgently needed to monitor the response to treatment in patients with pulmonary tuberculosis. The Xpert MTB/RIF assay is a commercially available real-time PCR that can be used to detect Mycobacterium-tuberculosis-specifi c DNA sequences in sputum samples. We therefore evaluated this assay with serial sputum samples obtained over 26 weeks from patients undergoing treatment for tuberculosis.
Introduction
Substantial progress has been made in global tuberculosis control but these gains are threatened by the global spread of drug-resistant tuberculosis. 1 The urgency of this situation calls for better treatment markers that can be used to detect insuffi cient treatment-the main cause of the emergence of resistance-early and easily. Additionally, the clinical development of the emerging new portfolio of tuberculosis drugs 2 could be accelerated if phase 2 and 3 trials could be greatly shortened and reliable surrogate markers used for the measurement of treatment success. 3 Current biomarkers that have been used as predictors of non-relapsing cure are sputum-smear microscopy and sputum-culture conversion, 4 both of which have shortcomings as markers for the measurement of treatment response. Sputum-smear microscopy is insensitive, operator dependent, and has been shown to be a poor predictor of treatment outcome. 5 It cannot be used to diff erentiate between Mycobacterium tuberculosis and non-tuberculosis mycobacteria reliably 6 and between live and dead bacilli. Sputum culture takes a long time, is prone to contamination, is expensive, and is rarely available in high-burden settings. In the absence of an ideal marker to measure treatment success in individuals, WHO currently recommends smear microscopy at month 2 to identify individuals at risk of poor treatment outcome. Also, in recent clinical studies of bedaquiline (TMC207) 7, 8 and delamanid (OPC-67683), 9 both biomarkers have been used to predict the therapeutic value of early drug regimens. Sputum-culture conversion at 8 weeks has some predictive value for the measurement of the sterilising activity of a novel regimen. 10 Potentially more promising, but not yet suffi ciently validated, is the time to culture positivity measured with semiautomated liquid culture. [11] [12] [13] Although several other M tuberculosis and human biomarkers have been studied over the past decade, 14, 15 including M tuberculosis DNA-based and RNA-based assays, [16] [17] [18] no new specifi c and accurate biomarkers of disease activity and relapse have yet been validated. Therefore, an urgent need exists for biomarkers that can be used to accurately measure bacillary clearance and identify individuals receiving insuffi cient treatment with high risk of tuberculosis recurrence. Furthermore, for innovative trial designs in which the aim is to reduce the size and duration of clinical trials, the use of faster surrogate endpoints for treatment effi cacy, disease activity, cure, and relapse will be indispensable. 3 WHO approved the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) for sputum-based rapid diagnosis of pulmonary tuberculosis and multidrug-resistant (MDR) tuberculosis. The assay can be used to accurately measure the M tuberculosis load beyond the detection limit of 131 organisms per mL in an in-vitro suspension. 19, 20 The Xpert MTB/RIF assay in patients with suspected tuberculosis and newly diagnosed cases of tuberculosis has been evaluated in several studies. [21] [22] [23] [24] The results of these studies suggested that the Xpert MTB/RIF assay is better than sputum-smear microscopy; its quantitative readouts correlate well with results of conventional solid and liquid cultures. [21] [22] [23] [24] Specifi cally, for the detection of tuberculosis and MDR-tuberculosis in HIV-positive individuals, a cost benefi t was noted compared with conventional smear microscopy. 25, 26 In this respect, detection of M tuberculosis DNA in serial sputum samples over time with the Xpert MTB/RIF assay could have the potential to replace conventional microbiological tests for monitoring response to tuberculosis treatment regimens. We evaluated the Xpert MTB/RIF assay in serial sputum samples obtained over 26 weeks of tuberculosis treatment from patients enrolled in the multicentre randomised clinical trial REMoxTB (ClinicalTrials.gov, NCT00864383).
Methods

Patients and study design
In this substudy, we obtained sputum samples from a subset of 221 participants enrolled in the multicentre, randomised clinical drug trial REMoxTB at two of the 47 clinical trial sites in Cape Town, South Africa, and Mbeya, Tanzania, between January, 2008, and April, 2010. In the REMoxTB trial, 1931 patients with previously untreated, drug-sensitive, smear-positive, pulmonary tuberculosis were enrolled between January, 2008, and January, 2012. HIV-positive patients with a CD4-cell count of fewer than 2·5 × 10⁸ per L or those already on antiretroviral treatment were excluded to avoid concomitant antiretroviral treatment, according to current practice at the time the protocol was prepared. All participants were treated for tuberculosis either with one of two treatment-shortening regimens of 4 months, in which moxifl oxacin was substituted for either isoniazid or ethambutol or with the standard 6 month regimen (2 months of isoniazid, rifampicin, ethambutol, and pyrazinamide followed by 4 months of isoniazid and rifampicin). Every patient was followed up for a total of 18 months. To avoid interference with the endpoints of the main treatment trial, the sample analysis with Xpert MTB/RIF was restricted until week 26 and all investigators were still masked to the treatment allocations. The results of the main study will become available in 2014.
Ethical and regulatory approval, granted by all local and national ethics committees and regulatory authorities, included the permission to undertake studies to improve treatment and diagnosis of tuberculosis.
Sputum samples
All participants were invited for regular visits to the study clinics and asked to provide one early morning sputum sample, which was spontaneously expectorated at home or at the clinics before treatment (week 0) and then weekly until week 8, followed by monthly sputum sample collection (weeks 12, 17, and 22) until week 26 after treatment initiation. Sputum specimens were processed by two study laboratories (Department of Biomedical Sciences, University of Stellenbosch, and the tuberculosis laboratory at the National Institute for Medical Research-Mbeya Medical Research Centre) in accordance with the standardised REMoxTB laboratory manual at both laboratories. Briefl y, a maximum of 10 mL of sample was homogenised and decontaminated with the N-acetyl-L-cysteine-sodium hydroxide procedure. 27 After centrifugation for 15 min at 4°C and 3000×g, the resulting pellet was stored at 4°C for further analyses.
30 μL of the concentrated sputum pellet was used for Ziehl-Neelsen staining followed by smear microscopy; 1·5 mL phosphate-buff ered saline (pH 6·8; Becton Dickinson, Sparks, MD, USA) was added and the pellet was resuspended. 500 μL of the suspension was used for evaluation in liquid culture with the Bactec MGIT960 system (MGIT; Becton Dickinson) and 150 μL in solid culture on Löwenstein-Jensen medium (Becton Dickinson) with standard protocols.
The remaining sputum pellet was mixed with 2 mL of the phosphate-buff ered saline and vortexed. 1 mL was processed for evaluation in the Xpert MTB/RIF assay according to the manufacturer's instructions by use of the GeneXpert Dx software (version 2.1 and 4.0) for automation of all PCR processing, reaction, and detection steps. The signals for fl uorescence were recorded, 
Data are number (%) or median (IQR), unless otherwise indicated. *For diff erence between sites, from Wilcoxon rank-sum test (binary variables) or two-sample test of proportions (continuous variables). analysed, and reported as semiquantitative readouts based on the minimal cycle threshold (C Tmin ), which is defi ned as one of fi ve probes specifi c for M tuberculosis complex becoming positive for detection.
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Statistical analysis
A negative result for smear microscopy was reported if no acid-fast bacilli were detected in at least 100 observation fi elds. Cultures in MGIT and on Löwenstein-Jensen media were judged to have a negative result if no mycobacterial growth was seen until 6 weeks and 8 weeks after incubation, respectively. A tuberculosis negative result for the Xpert MTB/RIF assay was generated automatically following an interpretative algorithm with the GeneXpert Dx software. Apart from calculating binary (positive, negative) variables for all test outcomes, results were processed to analyse them quantitatively: the intensity grades for smear (0, 1+, 2+, 3+, 4+) 28 and Löwenstein-Jensen (negative, <20 colonies, 1+, 2+, 3+) were coded into fi ve categories from 0 (negative) to 4. Time to positivity of MGIT and C Tmin of the Xpert MTB/RIF assay were used as quantitative outcomes and both were coded as 50 days and 50 cycles, respectively, if negative. Diagnostic test performance (sensitivity, specifi city, negative predictive value, positive predictive value) and Spearman rank correlations were calculated with standard formulae. In the absence of a perfect and accurate marker for tuberculosis disease activity, treatment response, or treatment outcome, either the combined result for smear microscopy, Löwenstein-Jensen culture, and MGIT culture, or each individual test was used as reference standard for the calculation of accuracy of the Xpert MTB/RIF assay. Diff erences between groups were tested for signifi cance with the two-sample proportion Z test for binary variables and the non-parametric Wilcoxon rank sum test for continuous variables because none of the results conformed to a normal distribution. Longitudinal C Tmin values over time were analysed by use of the non-linear least-squares estimation and non-linear mixed-eff ects models to better account for between-patient variability. The same biexponential model was used previously to fi t to these type of data. 18, 29 Stata software (version 12.1) was used for all statistical analyses with the exception of the non-linear mixed-eff ects models, which were fi t using the nlme package in R (version 2.9.0).
Role of the funding source
The study was a collaboration between the Global TB Alliance and the Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). This study was undertaken with permission from the REMox trial sponsor, but the study design, data collection, analysis, and interpretation, and writing of the report were done independently. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
2741 sputum specimens were obtained and analysed from 221 patients (131 in Cape Town, 90 in Mbeya) from weeks 0-26 after initiation of antituberculosis treatment. Table 1 shows the demographic characteristics of the patients. Figure 1 shows the qualitative data and table 2 the quantitative data for all tests at baseline and follow-up visits. Valid smear results were available for 2732 samples and valid Xpert MTB/RIF assay results for 2000 samples. After exclusion of acid-fast-bacillus-negative, but contaminated, cultures and those with no speciation result, 2324 and 2383 results for Löwenstein-Jensen and MGIT cultures, respectively, were included in the qualitative analysis (fi gure 1). There were 262 (11%) of 2383 acid-fast-bacillus-positive MGIT cultures showing contamination; these were excluded from the calculation To further elaborate the fi ndings, we used three diff erent statistical models to calculate the increase in C Tmin with the Xpert MTB/RIF assay (fi gure 2). In model 1, all negative results from the analysis were excluded. In model 2, a patient's fi rst negative result was imputed with a C Tmin of 50 and the subsequent negative results were excluded. In model 3, all negative results were imputed with a C Tmin of 50. The raw means (excluding negative results) with 95% CIs and raw medians were plotted by visit week. Figure 2 shows the fi tted line for each model with the raw means and medians for C Tmin . During the fi rst 7 weeks, when there were few negative results with the Xpert MTB/RIF assay, the lines for the mean and median values were close, indicating that the distribution of C Tmin was symmetrical. Assuming that the underlying distribution of C Tmin remains symmetrical throughout the observation period, the median is judged to be a better summary measure than the mean for calculations with the symmetrically distributed data for C Tmin because no assumptions are needed for values greater than the limit of detection, as is the case for models 1-3. Therefore, although, the increase in mean C Tmin suggested a shallower slope after week 8, the median continued to increase almost linearly until week 17. The lines for all models had linear slopes with slightly fl attened curves after week 12, depending on the inclusion of the negative results as determined by the model. Numerical values for the Table 2 : Quantitative data for all tests at baseline and follow-up visits medians at weeks 22 and 26 could not be calculated because more than 50% of patients had negative results in the Xpert MTB/RIF assay (fi gure 2). 1 To investigate the relation between C Tmin and the quantitative readouts for the smear, Löwenstein-Jensen, and MGIT assays, the Spearman rank correlation coeffi cient was calculated for each study timepoint. The magnitudes of the overall correlation coeffi cients ( ) over the entire 26 weeks were almost identical for smear (-0·74; p<0·0001), Löwenstein-Jensen (-0·73; p<0·0001), and MGIT (0·73; p<0·0001). Correlations were variable at discrete timepoints. C Tmin values correlated moderately Data for sensitivity, specifi city, positive predictive value, and negative predictive value are calculated against the reference standard. Samples with a negative smear result and missing culture result (Löwenstein-Jensen medium and Bactec MGIT960 system) were excluded from the analysis, and samples with a positive smear result and missing culture result (Löwenstein-Jensen medium and Bactec MGIT960 system) were included in the analysis. Table 3 : Diagnostic performance of Xpert MTB/RIF assay compared with the combined reference standard (smear microscopy, Löwenstein-Jensen medium, and Bactec MGIT960 system) with smear microscopy, Löwenstein-Jensen solid culture, and MGIT liquid culture in the fi rst 8 weeks but showed poorer correlation thereafter. We analysed the Xpert MTB/RIF assay for prediction of the binary smear and culture results at consecutive timepoints during treatment. Although the overall sensitivity of the assay was 97%, specifi city was low compared with the reference standard, which combined smear microscopy, MGIT, and Löwenstein-Jensen results (table 3) . At baseline and early follow-up visits, the putative poor specifi city of Xpert MTB/RIF assay was misleading because it was caused by false-negative microbiological results with the reference methods and a very low number of patients. Of greater relevance was the low specifi city at weeks 6-12, indicating a delayed Xpert MTB/RIF assay conversion compared with smear and culture methods (fi gure 1; table 3). The diagnostic performance of the Xpert MTB/RIF assay versus smear or culture methods alone did not show substantially diff erent values (table 4) . Notably, compared with MGIT, the Xpert MTB/RIF assay sensitivity and negative predictive value for culture positivity were both 100% from week 17 onwards (table 4; appendix).
We also investigated whether any change in C Tmin over time or absolute C Tmin could be used to predict a patient's conversion to a negative smear or culture result during treatment and did not fi nd it to be predictive (data not shown).
Discussion
The important fi ndings of our study are that quantitative Xpert MTB/RIF assay readouts for sputum M tuberculosis DNA as a biomarker correlate well with M tuberculosis smear and culture results during antituberculosis treatment. Positivity rates for sputum M tuberculosis DNA detection with Xpert MTB/RIF assay decline more slowly than do those with conventional sputum smear microscopy, solid culture, and liquid culture and seemed to be linear throughout treatment. Compared with a combined reference standard of smear and culture methods, the Xpert MTB/RIF assay had high sensitivity (97%) but poor specifi city (49%; table 3). To our knowledge, this study is the fi rst evaluation of the capacity of the Xpert MTB/RIF assay as an early sputum biomarker of response for monitoring tuberculosis treatment, and 
as a alternative for standard smear microscopy and culture (panel).
The Xpert MTB/RIF assay is assumed to be specifi c; it only detects DNA from intact M tuberculosis bacilli and contamination from free DNA is thought to be removed by a washing step. 20, 30 The assay, however, does not diff erentiate between viable, dormant, 31 and non-viable intact M tuberculosis bacilli that are shed during eff ective antituberculosis treatment. Furthermore, our fi ndingshigh rates of positive results at the end of the 6 month treatment-suggest that even DNA fragments from lysed or damaged bacteria could have been detected by use of Xpert MTB/RIF. Detection of these bacteria would explain the lengthy and constant slope, indicating a linear decay of DNA and dead mycobacteria, and is in contrast to the biphasic curves reported for culture or RNA-based assays. 12, 18 By contrast with DNA, the presence and amount of M tuberculosis RNA, particularly mRNA, correlated well with culture positivity and viable colony counts, respectively, 17, 18, 32 whereas DNA-based assays were also positive beyond culture conversion or even the end of successful treatment. 16, 33 The results of a recent study suggest that viable and non-viable M tuberculosis bacilli can be distinguished by use of propidiummonoazide, which enters damaged or non-viable mycobacteria, covalently binds to DNA after light-exposure, and prevents DNA amplifi cation, such as in the Xpert MTB/RIF assay. 34 The data show that detection of M tuberculosis DNA in sputum with the Xpert MTB/RIF assay in its current format cannot be used as a biomarker of disease activity and cannot replace conventional smear culture for the monitoring of patients undergoing treatment for tuberculosis. This is in agreement with the results of a recently reported study in which patients taking part in an early bactericidal activity trial were monitored by use of the Xpert MTB/RIF assay, and liquid and solid cultures; the Xpert MTB/RIF assay was the least suitable for the assessment of drug effi cacy. 8 Hence, several aspects of the capacity of the assay for use in monitoring tuberculosis treatment require further study: whether the specifi city of the Xpert MTB/RIF assay can be improved without aff ecting sensitivity through the prevention of DNA amplifi cation from dead bacteria; whether a positive or negative Xpert MTB/RIF assay result at the end of 6 months of tuberculosis treatment can be used to provide prognostic information about treatment failure and relapse; and the prognostic relevance of baseline quantitative values or the timepoint of conversion to negativity, which was shown for time to positivity with MGIT. 13 This study has several advantages because it was nested in a clinical trial. A large number of samples (n=2741) were obtained and processed under standardised and highly monitored conditions, as shown by the robust and high-quality data generated at both study sites for the Xpert MTB/RIF assay, and smear and culture methods. The similarity of the data between diff erent sites suggests that our fi ndings could not be attributed to technical factors. The number of patients lost to follow-up was very low and the falling numbers of available results during follow-up are usually the result of patients being unable to produce sputum samples at the end of an eff ective treatment.
A limitation of this study is that the results of the Xpert MTB/RIF assay could not be linked with clinical outcomes such as cure and relapse. Since the REMoxTB trial is still in progress, information about the allocated tuberculosis treatment or the presence of drug resistance in relation to the patients' responses to treatment was not available for data analysis in this study. However, because the Xpert MTB/RIF assay is widely available in many countries, clinicians might be starting to use this assay speculatively to monitor patients, as is commonly done with microscopy. Therefore, the results of our study are important because they show that the Xpert MTB/RIF assay is less responsive for the monitoring of tuberculosis treatment than is smear microscopy.
Notably, however, the absence of an adequate reference standard, and the consecutive use of smear microscopy and culture as imperfect surrogates, might have distorted the results of the diagnostic performance of the Xpert MTB/RIF assay. The results are further limited by our study being undertaken in only two sites in Africa and in a population of patients who were not severely ill.
Our data indicate that the Xpert MTB/RIF assay in its current format is not suitable for the monitoring of
Panel: Research in context
Systematic review
We did an online search of the PubMed database on Jan 31, 2011, to identify scientifi c articles about the Xpert MTB/RIF assay published since Jan 1, 2010, using the terms "Xpert" or "GeneXpert" and "tuberculosis". Only articles published in English were selected. Six articles were reviewed. The results of these studies showed the ability of this testing platform as a primary diagnostic method for detection of Mycobacterium tuberculosis mainly in expectorated sputum samples from patients with untreated tuberculosis. [20] [21] [22] [23] [24] Although several studies have been planned, there are no reports of the use of the Xpert MTB/RIF assay to monitor tuberculosis treatment in the context of a clinical trial.
Interpretation
Previous research has shown that the Xpert MTB/RIF assay has a high specifi city in the diagnosis of M tuberculosis with improved sensitivity compared with smear microscopy and culture. Thus, the available evidence shows that the Xpert MTB/RIF assay is useful as a primary diagnostic aid. In view of the need for improved biomarkers, researchers have speculated that the assay might be used to monitor treatment response and the samples available to us provided a unique opportunity to test this hypothesis. As a result, the Xpert MTB/RIF assay was compared with the standard method to assess its usefulness for treatment monitoring and its potential as a biomarker. We concluded that, in its current format, the Xpert MTB/RIF assay cannot be used to monitor antituberculosis treatment due to its slow decline in positivity compared with smear microscopy and culture. Future technological change that would eliminate the signal from dead bacilli could overcome this problem and provide a useful biomarker for use in resource-poor settings.
tuberculosis treatment and, thus, cannot replace standard smear microscopy and culture. Therefore, technical improvements in the Xpert MTB/RIF assay that prevent the assay from detecting DNA from non-viable or even damaged bacteria will be needed before the test is suitable for monitoring patients in settings where it has already replaced smear microscopy as a diagnostic test. Larger studies with longer follow-up are needed to clarify the prognostic relevance of the Xpert MTB/RIF assay results for the prediction of treatment failure or relapse.
